Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Randomized Study to Estimate Safety, PK, and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Standard-of-Care Following IV Echinocandin Therapy in the Treatment of Invasive Candidiasis in Hospitalized Nonneutropenic Adults

NCT02244606 is registered in ClinicalTrials.gov with Scynexis, Inc. as lead sponsor.

NCT NCT02244606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02244606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Randomized Study to Estimate Safety, PK, and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Standard-of-Care Following IV Echinocandin Therapy in the Treatment of Invasive Candidiasis in Hospitalized Nonneutropenic Adults
Lead sponsor
Scynexis, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2014
Completion date
August 31, 2016
Enrollment
27 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

candidemia, candidiasis, invasive, mycoses